Venetoclax plus Azacitidine versus Standard intensive Chemotherapy for Patients with newly diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations eligible for intensive Treatment (VINCENT)
Latest Information Update: 03 Sep 2026
At a glance
- Drugs Mitoxantrone (Primary) ; Venetoclax (Primary) ; Azacitidine; Cytarabine; Daunorubicin; Gemtuzumab ozogamicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms VINCENT
Most Recent Events
- 27 Aug 2026 Planned End Date changed from 1 Jun 2028 to 1 Sep 2030.
- 27 Aug 2026 Planned primary completion date changed from 1 Sep 2028 to 1 Sep 2030.
- 10 Feb 2025 According to Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition, Currently 18 centers are active.